Novo Nordisk A/S (NYSE:NVO) Position Boosted by Eldred Rock Partners LLC

Eldred Rock Partners LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,035 shares of the company's stock after purchasing an additional 20,184 shares during the quarter. Novo Nordisk A/S makes up approximately 2.0% of Eldred Rock Partners LLC's holdings, making the stock its 29th biggest position. Eldred Rock Partners LLC's holdings in Novo Nordisk A/S were worth $6,669,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Center for Financial Planning Inc. increased its holdings in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the period. Strategic Investment Solutions Inc. IL raised its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth about $29,000. Transce3nd LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $39,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NVO shares. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. BNP Paribas started coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Finally, Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and an average price target of $128.00.

Novo Nordisk A/S Stock Down 2.7%

Shares of Novo Nordisk A/S stock traded down $1.93 on Tuesday, hitting $70.90. 8,812,399 shares of the company's stock traded hands, compared to its average volume of 6,858,163. The firm's 50-day moving average is $65.60 and its 200 day moving average is $81.22. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The stock has a market cap of $318.17 billion, a P/E ratio of 21.55, a PEG ratio of 0.90 and a beta of 0.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion during the quarter. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.